Online inquiry

IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3703MR)

This product GTTS-WQ3703MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MSLN gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001177355.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10232
UniProt ID Q13421
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3703MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10161MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ10813MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ5921MR IVTScrip™ mRNA-Anti-CD274, CK-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CK-301
GTTS-WQ78MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ4560MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936564
GTTS-WQ8656MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ7052MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ3049MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW